CKD management has changed substantially. SGLT2 inhibitors now have a kidney-protective role independent of diabetes. Albuminuria is as important as eGFR for risk stratification. The goal is slowing progression and reducing cardiovascular risk — not just watching the creatinine.
CLINICAL PRINTABLE
Coming Soon.
A one-page Chronic Kidney Disease Management clinical reference is on the way.
1 · Recognition / Staging
- CKD is defined as kidney damage or eGFR <60 mL/min/1.73m² for ≥3 months. Staging uses both eGFR (G1–G5) and albuminuria (A1–A3) — the combination determines risk and guides management intensity.
- Identify the cause: diabetic nephropathy, hypertensive nephrosclerosis, glomerulonephritis, polycystic kidney disease, obstructive uropathy, or other. Cause informs prognosis and specific treatment.
- Distinguish CKD from AKI and acute-on-chronic — prior creatinine values, imaging (kidney size), and clinical context are essential.
- Screen for complications at each stage: anemia (eGFR <60), metabolic acidosis (eGFR <45), hyperkalemia, hyperphosphatemia, secondary hyperparathyroidism, and volume overload.
2 · Treatment Pathway
Blood pressure control
Target BP <130/80 mmHg in CKD. ACE inhibitor or ARB is preferred in CKD with albuminuria — reduces proteinuria and slows progression independent of BP effect. Monitor creatinine and potassium after initiation.
SGLT2 inhibitors
SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) reduce CKD progression and cardiovascular events in patients with CKD and albuminuria — now recommended regardless of diabetes status in appropriate patients.
Finerenone
Finerenone (non-steroidal MRA) reduces CKD progression and cardiovascular events in diabetic CKD with albuminuria — additive benefit to ACE/ARB and SGLT2 inhibitor.
Glycemic control
In diabetic CKD, optimize glycemic control. SGLT2 inhibitors and GLP-1 agonists have kidney-protective effects. Adjust medication doses for eGFR — metformin hold at eGFR <30, sulfonylurea caution.
Metabolic acidosis
Treat metabolic acidosis (bicarbonate <22 mEq/L) with oral sodium bicarbonate — acidosis accelerates CKD progression and muscle catabolism.
Anemia of CKD
Iron deficiency is common and should be corrected first. Erythropoiesis-stimulating agents (ESAs) for Hgb <10 g/dL when iron-replete — target Hgb 10–11.5 g/dL, not higher.
Mineral bone disease
Monitor phosphorus, calcium, PTH, and 25-OH vitamin D. Dietary phosphorus restriction, phosphate binders, and vitamin D supplementation as indicated.
3 · Expected Response / Monitoring
- ACE inhibitor/ARB initiation may cause a small creatinine rise (up to 30%) — this is expected hemodynamic change and should not prompt discontinuation unless accompanied by hyperkalemia, hypotension, or volume depletion.
- SGLT2 inhibitors cause an initial eGFR dip of 3–5 mL/min/1.73m² — this is expected and does not indicate harm. Long-term eGFR trajectory is preserved.
- Slowing CKD progression is the goal — complete stabilization is not always achievable. Monitor eGFR trajectory over time.
4 · Escalation
- Acute-on-chronic kidney injury with severe electrolyte/acid-base disturbance, pulmonary edema, uremic symptoms, or rapidly worsening renal function.
- Do not mistake an acute creatinine rise for routine CKD progression without evaluating reversible causes — obstruction, volume depletion, nephrotoxins, and AKI are treatable.
- Nephrology referral: eGFR <30, rapidly declining eGFR, significant proteinuria, uncertain diagnosis, or preparation for renal replacement therapy.
- Dialysis planning: begin education and access planning (AV fistula) when eGFR approaches 20 mL/min/1.73m².
Apply It · Change One Detail
APPLY IT
CKD with albuminuria and stable potassium develops a small creatinine rise after ACE inhibitor initiation. That can reflect expected hemodynamic change and should be interpreted in context — not reflexively stopped.
CHANGE ONE DETAIL
Change one detail — large creatinine rise with hypotension, volume depletion, or hyperkalemia — and reassessment is required. Hold the ACE inhibitor, address the reversible cause, and reassess.
Bottom Line
CKD management is kidney protection plus cardiovascular protection, guided by eGFR AND albuminuria. Both dimensions matter.
EVIDENCE & REFERENCES
- KDIGO 2024 CKD Guideline. Kidney Int. 2024;105(4S):S117-S314. doi:10.1016/j.kint.2023.10.018
- Heerspink HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446. doi:10.1056/NEJMoa2024816